Skip to content

OUR COMPANY

We are a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ophthalmic diseases

OUR MISSION


Kodiak aims to prevent and treat the leading causes of blindness in the developed world

TRAILBLAZING SCIENCE

OUR CREATIVE AND THOUGHTFUL FOUNDATION

“GO-TO” MEDICINES

OUR CHALLENGE TO THE STATUS QUO

SINGULAR FOCUS IN OPHTHALMOLOGY

OUR 24/7/365

THE TEAM


Together, our team has acquired decades of experience needed to solve some of the most challenging issues in ophthalmology

BOARD OF DIRECTORS


OUR HISTORY


2009

Jul 2009
Company is founded in Palo Alto, California and focuses on conjugating antibodies and biopolymers to form new medicines

2018

July 2018
Kodiak initiates its first Phase 1a clinical study of KSI-301, an antibody biopolymer conjugate, in patients with diabetic macular edema (DME)